摘要
葡萄糖目标范围内时间(TIR)是临床上血糖达标的新指标,也可以用于评估胰岛素的治疗效果和指导胰岛素的治疗。依柯胰岛素作为正在研发中的胰岛素周制剂,与传统胰岛素日制剂相比,作用时间显著延长,同时其疗效及安全性也备受关注。依柯胰岛素3期临床试验ONWARDS系列研究及事后分析通过TIR等指标,为全面评估依柯胰岛素的有效性和安全性提供了进一步的循证证据。
Time in range(TIR)is a new indicator for evaluating blood glucose control status in clinical practice.TIR can also be used to evaluate the therapeutic effect of insulin and further guide insulin treatment.As once-weekly insulin administration undergoing research&development,insulin icodec has a significantly longer action time compared to traditional once-daily insulin.Its efficacy and safety have drawn much attention.The ONWARDS serial phase 3 clinical trials and post-hoc analysis provides evidence-based enlightenment to comprehensively evaluate insulin efficacy and safety with TIR and other indicators.
作者
秦贵军
QIN Guijun(The First Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450052,China)
出处
《药品评价》
CAS
2023年第9期1041-1045,共5页
Drug Evaluation
